Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 6
2016 1
2017 4
2018 1
2019 3
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Rubio-Pérez L, Lázaro-Gorines R, Harwood SL, Compte M, Navarro R, Tapia-Galisteo A, Bonet J, Blanco B, Lykkemark S, Ramírez-Fernández Á, Ferreras-Gutiérrez M, Domínguez-Alonso C, Díez-Alonso L, Segura-Tudela A, Hangiu O, Erce-Llamazares A, Blanco FJ, Santos C, Rodríguez-Peralto JL, Sanz L, Álvarez-Vallina L. Rubio-Pérez L, et al. Among authors: lykkemark s. Oncoimmunology. 2023 Apr 24;12(1):2205336. doi: 10.1080/2162402X.2023.2205336. eCollection 2023. Oncoimmunology. 2023. PMID: 37114242 Free PMC article.
The coming of age of engineered multivalent antibodies.
Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, Álvarez-Vallina L. Nuñez-Prado N, et al. Among authors: lykkemark s. Drug Discov Today. 2015 May;20(5):588-94. doi: 10.1016/j.drudis.2015.02.013. Epub 2015 Mar 7. Drug Discov Today. 2015. PMID: 25757598 Review.
Selection strategies for anticancer antibody discovery: searching off the beaten path.
Sánchez-Martín D, Sørensen MD, Lykkemark S, Sanz L, Kristensen P, Ruoslahti E, Álvarez-Vallina L. Sánchez-Martín D, et al. Among authors: lykkemark s. Trends Biotechnol. 2015 May;33(5):292-301. doi: 10.1016/j.tibtech.2015.02.008. Epub 2015 Mar 26. Trends Biotechnol. 2015. PMID: 25819764 Free PMC article. Review.
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Blanco B, Ramírez-Fernández Á, Bueno C, Argemí-Muntadas L, Fuentes P, Aguilar-Sopeña Ó, Gutierrez-Agüera F, Zanetti SR, Tapia-Galisteo A, Díez-Alonso L, Segura-Tudela A, Castellà M, Marzal B, Betriu S, Harwood SL, Compte M, Lykkemark S, Erce-Llamazares A, Rubio-Pérez L, Jiménez-Reinoso A, Domínguez-Alonso C, Neves M, Morales P, Paz-Artal E, Guedan S, Sanz L, Toribio ML, Roda-Navarro P, Juan M, Menéndez P, Álvarez-Vallina L. Blanco B, et al. Among authors: lykkemark s. Cancer Immunol Res. 2022 Apr 1;10(4):498-511. doi: 10.1158/2326-6066.CIR-21-0853. Cancer Immunol Res. 2022. PMID: 35362043 Free PMC article.
Human Mast Cell Sensitization with IgE Increases miRNA-210 Expression.
Just J, Munk Ipsen P, Kruhøffer M, Lykkemark S, Skjold T, Schiøtz PO, Hoffmann HJ. Just J, et al. Among authors: lykkemark s. Int Arch Allergy Immunol. 2019;179(2):102-107. doi: 10.1159/000496513. Epub 2019 Apr 9. Int Arch Allergy Immunol. 2019. PMID: 30965334 Free article.
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
Compte M, Harwood SL, Muñoz IG, Navarro R, Zonca M, Perez-Chacon G, Erce-Llamazares A, Merino N, Tapia-Galisteo A, Cuesta AM, Mikkelsen K, Caleiras E, Nuñez-Prado N, Aznar MA, Lykkemark S, Martínez-Torrecuadrada J, Melero I, Blanco FJ, Bernardino de la Serna J, Zapata JM, Sanz L, Alvarez-Vallina L. Compte M, et al. Among authors: lykkemark s. Nat Commun. 2018 Nov 15;9(1):4809. doi: 10.1038/s41467-018-07195-w. Nat Commun. 2018. PMID: 30442944 Free PMC article.
21 results